BICYCLE THERAPEUTICS PLC |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 21.36 USD | -3.70% |
|
-6.68% | +18.14% |
Presenter SpeechLee Hung (Analysts)[Audio Gap] Morgan Stanley Global Healthcare conference, I'...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Bicycle Therapeutics plc is a United Kingdom-based clinical-stage biopharmaceutical company developing a novel class of medicines, referred to as Bicycle molecules, for diseases that are underserved by existing therapeutics. Bicycle molecules are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural geometry. The Company is evaluating BT8009, a Bicycle Toxin Conjugate (BTC) targeting Nectin-4, a well-validated tumor antigen; BT5528, a BTC targeting EphA2, a historically undruggable target, and BT7480, a Bicycle Tumor-Targeted Immune Cell Agonist (Bicycle TICA) targeting Nectin-4 and agonizing CD137, in Company-sponsored clinical trials. Additionally, the Company is developing Bicycle Radio Conjugates (BRC) for radiopharmaceutical use and, through various partnerships, is exploring the use of Bicycle technology to develop therapies for diseases beyond oncology. Its product candidates also include BT1718 and BT7455.
Calendar
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
13
Last Close Price
21.36
USD
Average target price
44
USD
Spread / Average Target
+105.99%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +18.14% | 914M | |
| +9.42% | 115B | |
| +11.84% | 106B | |
| -14.15% | 21.84B | |
| -1.05% | 21.96B | |
| -5.29% | 19.21B | |
| -38.29% | 17.71B | |
| -4.16% | 18.08B | |
| +7.99% | 14.32B | |
| +36.24% | 12.42B |
- Stock Market
- Equities
- BCYC Stock
- News Bicycle Therapeutics plc
- Transcript : Bicycle Therapeutics plc Presents at Morgan Stanley 21st Annual Global Healthcare Conference 2023, Sep-12-2023 10
